# Dudi Klein

> Dudi Klein is a Series A investor at Assuta Medical Centers backing Health Care and Medical. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Assuta Medical Centers](https://shizune.co/investors/profile/assuta-medical-centers)
- Location: Tel Aviv, Israel
- Total investments: 3
- Last investment: Jul 2023
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/dudiklein
- Website: https://x.com/KleinDudi

Dudi Klein is a Series A investor at Assuta Medical Centers in Tel Aviv focused on Health Care and Medical. Highly passionate entrepreneurial executive, tenacious, results focused leader with 16+ years of experience - gets things done with limited resources under time constraints.I enjoy taking on new projects and challenges, have ability to successfully execute strategic products by bringing in highly set goals, business development and networkingskills that uplift the company and team, strong technical understanding and a keen eye for detail. I believe one of my major strengths is my ability and passion for motivation and coaching people for personal and corporate success.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 100% |
| Medical | 2 | 67% |
| mHealth | 2 | 67% |
| Medical Device | 2 | 67% |
| Mobile Apps | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 33% |
| Series B | 1 | 33% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Israel | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Append Medical | Append Medical develops a next-generation transcatheter Left Atrial Appendage (LAA) closure system.The Append Medical solution is in the pre-clinical in-vivo trial phase. It is intended to become a differentiated solution in the LAA closure market, which has been estimated to reach $25B within several years. This is the second-fastest growingsegment of the medical device market, with potential sales of $500M in 2019. Append Medical is a member of MEDX Xelerator, a medtech incubator backed by Boston Scientific, Intellectual Ventures, MEDX Ventures and Sheba Medical Center. | $4.4M | Series A | Jul 06, 2023 |  |
| Cynerio | Cynerio is a cybersecurity company focused on protecting healthcare environments, specifically targeting medical, clinical, IoT, and operational technology (OT) devices. Its unified platform includes three core modules: Network Detection and Response for Healthcare (NDR‑H), which offers deep packet inspection, real-time threat detection, andbehavioral anomaly responses; Medical Device Security, which automatically discovers connected devices, assesses risk, and provides mitigation strategies like micro-segmentation and patching; and Complete Asset Visibility, which delivers a centralized inventory of IT, OT, IoT, and IoMT devices with customizable dashboards and compliance reporting.The company integrates with Microsoft Sentinel and is a member of the Microsoft Intelligent Security Association (MISA), enhancing interoperability with cloud-native security operations platforms. Cynerio has received industry recognition, ranking among the top two vendors in the 2025 Best in KLAS report for Healthcare IoT Security with a score of 94 out of 100. It was also awarded Frost & Sullivan’s 2025 North American Enabling Technology Leadership Award.Cynerio's solutions are used globally, including deployments across major NHS trusts in the UK such as Barts Health and the Cheshire and Merseyside systems. These implementations helped rapidly identify unmonitored devices and apply proactive segmentation, significantly improving cybersecurity readiness in healthcare settings. | $30M | Series B | May 19, 2021 |  |
| Medisafe | Medisafe is a digital patient engagement platform, empowering patients to stay on top of all their medications. Its approach leverages the billions of data points collected to personalize patient engagement and improve adherence and persistence to medications.By addressing the major challenges of medication management utilizing a datascience-driven approach, Medisafe improves patient adherence and quality of care. The company provides its pharma and payer partners the opportunity to engage each patient on an individual level, supporting them throughout the entire patient journey, and provides unique insights on behavior patterns critical for improving the patient experience. Medisafe had shown over numerous studies, both retrospective with tens of thousands of patients as well as RCTs, that its solutions improve adherence by up to 20%.Founded following an accidental insulin overdose of the founder's father, the Medisafe solution currently has nearly 5 million registered users across iOS and Android smartphones, tablets, wearables, and Web solutions, who have recorded over 2 billion medication doses. Nearly 200,000 users have rated the app an average of 4.7 out of 5 stars in the App Store and Google Play store, making it the Top Rated solution in the category. Their accolades include Gartner Cool Vendors, Traction winner (Health 2.0 startup competition), Fast Company Most Innovative in Healthcare, Google and Apple Editors' Choice and Top Developer, etc. | $30M | Series C | Feb 25, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Consensus Business Group](https://shizune.co/investors/profile/consensus-business-group) — VC Fund, 2 deals together
- [7wire Ventures](https://shizune.co/investors/profile/7wire-ventures) — VC Fund, 1 deal together
- [Accelmed](https://shizune.co/investors/profile/accelmed) — VC Fund, 1 deal together
- [Leumi Partners](https://shizune.co/investors/profile/leumi-partners) — VC Fund, 1 deal together
- [lool ventures](https://shizune.co/investors/profile/lool-ventures) — VC Fund, 1 deal together
- [MTIP AG](https://shizune.co/investors/profile/medtech-innovation-partners) — VC Fund, 1 deal together

## About Assuta Medical Centers

VC Fund



3 contacts available at Assuta Medical Centers.

| Name | Title | Profile |
| --- | --- | --- |
| Ari Shamiss | CEO | https://shizune.co/investors/profile/ari-shamiss |
| Dudi Klein | Head of Ventures & Innovation Division | https://shizune.co/investors/profile/dudi-klein |
| Yaniv Levinson | Sales Director - Assuta Medical Center, Medical Tourism | https://shizune.co/investors/profile/yaniv-levinson |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Dudi Klein invest in?

Dudi Klein invests primarily in Health Care, Medical and mHealth startups, most often at Series A and Series B stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Dudi Klein last invest?

The most recent investment recorded for Dudi Klein closed in Jul 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co
